文献速递心境障碍

难治性抑郁症:定义、患病率、识别、管理与研究性干预

Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.
PubMed 文献 · World Psychiatry · 2023-01-01

难治性抑郁症(TRD)常见且带来多重公共卫生影响,但目前缺乏共识定义,导致患病率估计、风险因素识别和临床决策存在异质性。FDA与EMA采用最常用定义(足量足疗程且依从治疗下对至少两种抗抑郁药反应不足),估计至少30%的抑郁症患者符合该定义。静脉氯胺酮和鼻内艾司氯胺酮对TRD有效,部分第二代抗精神病药作为增效治疗有效,rTMS和ECT也被确立为有效干预。

要点

  • TRD缺乏共识定义,FDA/EMA定义(至少两种抗抑郁药足量足疗程反应不足)最常用,约30%抑郁症患者符合。
  • 相当比例TRD实为假性难治(治疗不充分或依从性差),需先排除。
  • 静脉氯胺酮、鼻内艾司氯胺酮、rTMS和ECT对TRD有效;部分第二代抗精神病药作为增效治疗有效。

核心结论

  • TRD常见且缺乏共识定义,影响患病率估计和临床决策。
  • FDA/EMA定义(至少两种抗抑郁药足量足疗程且依从治疗下反应不足)最常用,估计至少30%抑郁症患者符合。
  • 静脉氯胺酮和鼻内艾司氯胺酮(联合抗抑郁药)对TRD有效。
  • 部分第二代抗精神病药作为抗抑郁药增效治疗对部分反应者有效,但仅奥氮平-氟西汀组合在FDA定义的TRD中研究过。
  • rTMS(包括加速θ爆发式TMS)和ECT对TRD有效。

研究设计与样本

  • 原文为综述,未报告系统检索范围。

主要发现

  • TRD定义众多且概念框架差异大,缺乏共识定义妨碍患病率精确估计和风险因素识别。
  • 至少30%的抑郁症患者符合FDA/EMA的TRD定义。
  • 相当比例TRD患者为假性难治,原因包括治疗试验不充分或依从性差。
  • 静脉氯胺酮和鼻内艾司氯胺酮(联合抗抑郁药)对TRD有效。
  • 奥氮平-氟西汀组合是唯一在FDA定义的TRD中研究过的第二代抗精神病药组合。

关键数值与推荐

  • FDA和EMA采用的定义:对至少两种抗抑郁药在治疗试验充分且依从治疗的情况下反应不足。
  • 估计至少30%的抑郁症患者符合该TRD定义。
  • 静脉氯胺酮和鼻内艾司氯胺酮(联合抗抑郁药)对TRD有效。
  • 部分第二代抗精神病药(阿立哌唑、依匹哌唑、卡利拉嗪、喹硫平XR)作为增效治疗对部分反应者有效。
  • 重复经颅磁刺激(rTMS)获FDA批准用于TRD,加速θ爆发式TMS近期显示有效;ECT被视为有效的急性期和维持期干预,初步证据提示其与急性静脉氯胺酮相比非劣效。

临床怎么用

  • 临床应首先排除假性难治(治疗不充分或依从性差)。
  • 对TRD可考虑静脉氯胺酮或鼻内艾司氯胺酮(联合抗抑郁药)。
  • 部分第二代抗精神病药可作为抗抑郁药增效治疗用于部分反应者。
  • rTMS和ECT是TRD的有效干预选择。
  • 延长抗抑郁药试验、换药和联合抗抑郁药的证据不一;手动化心理治疗单独使用未确立有效,但联合常规抗抑郁药可提供显著症状缓解。

局限性

  • 缺乏TRD共识定义妨碍患病率精确估计和风险因素识别。
  • TRD定义概念框架差异大导致临床实践决策异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment-resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision-making and health outcomes does not currently exist. Instead, a plethora of definitions have been proposed, which vary significantly in their conceptual framework. The absence of a consensus definition hampers precise estimates of the prevalence of TRD, and also belies efforts to identify risk factors, prevention opportunities, and effective interventions. In addition, it results in heterogeneity in clinical practice decision-making, adversely affecting quality of care. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have adopted the most used definition of TRD (i.e., inadequate response to a minimum of two antidepressants despite adequacy of the treatment trial and adherence to treatment). It is currently estimated that at least 30% of persons with depression meet this definition. A significant percentage of persons with TRD are actually pseudo-resistant (e.g., due to inadequacy of treatment trials or non-adherence to treatment). Although multiple sociodemographic, clinical, treatment and contextual factors are known to negatively moderate response in persons with depression, very few factors are regarded as predictive of non-response across multiple modalities of treatment. Intravenous ketamine and intranasal esketamine (co-administered with an antidepressant) are established as efficacious in the management of TRD. Some second-generation antipsychotics (e.g., aripiprazole, brexpiprazole, cariprazine, quetiapine XR) are proven effective as adjunctive treatments to antidepressants in partial responders, but only the olanzapine-fluoxetine combination has been studied in FDA-defined TRD. Repetitive transcranial magnetic stimulation (TMS) is established as effective and FDA-approved for individuals with TRD, with accelerated theta-burst TMS also recently showing efficacy. Electroconvulsive therapy is regarded as an effective acute and maintenance intervention in TRD, with preliminary evidence suggesting non-inferiority to acute intravenous ketamine. Evidence for extending antidepressant trial, medication switching and combining antidepressants is mixed. Manual-based psychotherapies are not established as efficacious on their own in TRD, but offer significant symptomatic relief when added to conventional antidepressants. Digital therapeutics are under study and represent a potential future clinical vista in this population.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023. PMID: 37713549. doi:10.1002/wps.21120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。